TRAF2 and plasma cell myeloma: Several studies showed that loss-of-function mutations of TRAF2, TRAF3 or cIAP1/2 protects NIK from proteasomal degradation leading to accumulation of NIK and subsequent constitutive noncanonical NF-κB activation in multiple myeloma cells [5], [6].